egalet corporation  management follow egaletcorpmanagementexecutive management egalet’s management team has extensive experience in the pharmaceutical and biotechnology industry and has a track record of successfully developing and commercializing productsegalet corporation robert radiepresident and chief executive officer mr radie is president chief executive officer and a member of egalet’s board of directors and has been since march  mr radie has had a successful career with more than three decades in the industry and has been responsible for the sale of five companies in  mr radie led the sale of vicuron pharmaceuticals to pfizer for  billion and most recently he was responsible for the sale of topaz pharmaceuticals inc to sanofi pasteur for an undisclosed amount mr radie served in senior management positions with a number of pharmaceutical and biotechnology companies including prestwick pharmaceuticals inc morphotek inc vicuron pharmaceuticals inc and served as a director of affinium pharmaceuticals ltd from july  to march  when a majority of affinium’s assets were acquired by a third party mr radie began his career in the life sciences at eli lilly and company where he worked for  years in sales and marketing positions with increasing levels of responsibility mr radie serves on the board of paratek pharmaceuticals a biopharmaceutical company pennsylvania bio an industry group supporting pennsylvania life sciences companies veloxis a public commercialstage company and horse power for life a nonprofit organization dedicated to improving the quality of life for individuals diagnosed with cancer mr radie received his bs in chemistry from boston collegeegalet corporation stan musialchief financial officer mr musial has served as our chief financial officer since april  from june  to march  mr musial was selfemployed acting as an independent consultant in the fields of financial management and accounting services from january  to may  mr musial served as chief financial officer of prism pharmaceuticals inc a specialty pharmaceutical and drug development company prior to joining prism pharmaceuticals mr musial was vice president finance and chief financial officer for strategic diagnostics inc a publicly held biotechnology company from  to  mr musial began his career with kpmg llp a professional services company mr musial received a bs in accounting from the pennsylvania state university and an mba from temple university he is a certified public accountant in the commonwealth of pennsylvaniaegalet corporation mark strobeck phdexecutive vice president and chief operating officer dr strobeck is executive vice president and chief operating officer a position he’s held since october  he joined egalet in february  as chief business officer cbo previously dr strobeck was president and chief executive officer of corridor pharmaceuticals which he successfully sold to astrazeneca and chief business officer of topaz pharmaceuticals which he sold to sanofi pasteur dr strobeck was chief business officer at trevena inc and vice president of business development at glaxosmithkline before working at these healthcare companies dr strobeck was a venture capitalist at sr one ltd the wholly owned venture capital arm of gsk and euclid sr partnersdr strobeck earned a phd in pharmacology and cell biophysics from the university of cincinnati completed a postdoctoral fellowship in cardiovascular medicine at the university of pennsylvania and received his bachelor’s degree from st lawrence universityegalet corporation barbara a carlinchief accounting officer ms carlin is our chief accounting officer a position she’s held since january  she joined egalet in january  as vice president finance and administration for more than  years ms carlin has provided financial and operational leadership to public and privately held companies with a focus on the emerging growth life sciences community during that time she worked at several biotechnology and specialty pharmaceutical companies including topaz pharmaceuticals inc moksha pharmaceuticals inc genaera corporation and vicuron pharmaceuticals inc she also served in various roles in finance and accounting at publically held companies in the professional services and publishing space ms carlin started her career in accounting at deloitte and touche llp she earned her bachelor’s degree in accounting from st joseph’s university and is a certified public accountant in the commonwealth of pennsylvaniaegalet corporation e blair clarkschoebsenior vice president communications ms clarkschoeb senior vice president communications leads our investor relations public relations advocacy relations and government affairs work she has two decades of experience helping healthcare companies develop unique and effective communications programs prior to joining egalet in february  ms clarkschoeb led her own consulting business working with pharmaceutical and biotechnology companies such as sanofi syndax horizon pharmaceuticals and topaz pharmaceuticals prior to that she was senior associate at wo director of investor relations at burns mcclellan director of corporate finance at the medicines company and a healthcare investment banker at donaldson lufkin and jenrette ms clarkschoeb received her bachelor’s degree from harvard universityegalet corporation jeffrey m dayno mdchief medical officer dr jeffrey dayno joined egalet as our chief medical officer in july  he spent ten years in clinical and academic medicine before moving into the pharmaceutical industry he served as vice president global medical affairs at viropharma inc from august  to may  prior to joining viropharma dr dayno was the chief medical officer at labopharm inc a drug delivery technology company based in montreal canada where he first started working in the field of abusedeterrent opioid product development before labopharm he was vice president of medical affairs at cephalon inc from  to  dr dayno started his career in the pharmaceutical industry in  at merck  co inc where he spent  years in positions of increasing responsibility in the medical and scientific affairs division before moving into leadership roles in the pharmaceutical and biotechnology industry he held a number of clinical appointments including assistant professor of neurology jefferson medical college and medical director of the jefferson health system stroke center network dr dayno earned his medical degree from temple university school of medicine completed a fellowship in stroke and cerebrovascular disorders in the department of neurology at henry ford hospital a national institutes of health nih clinical research center for stroke and headache and was board certified in neurology dr dayno is currently a member of the board of visitors of temple university school of medicine and was a former chairman of the philadelphia stroke councilegalet corporation karsten lindhardt msc phdsenior vice president research and development dr lindhardt has been our senior vice president of research and development since december  from april  to december  he served as vice president research and development and previously served as our senior director of portfolio management and alliance manager from march  to april  from august  to march  dr lindhardt served as the director of portfolio management for our predecessor egalet as and as a project manager from march  to august  before joining egalet as dr lindhardt served in management positions for curalogic as and osi pharmaceuticals and as a clinical pharmacologist for ferring pharmaceuticals and novo nordisk as dr lindhardt received an msci in pharmaceutics a phd in pharmaceutical development and pharmacology each from the royal danish school of pharmacy and a diploma of business excellence dbe from columbia university and copenhagen business schoolegalet corporation paul c varkisenior vice president and general counsel mr varki is our senior vice president and general counsel a position he has held since november  prior to egalet he served as assistant general counsel at glaxosmithkline gsk providing global legal support for research and development before that position he served as senior counsel for gsk’s vaccines business unit within north america and counsel for marketed products within the us pharmaceuticals business mr varki practiced food and medical device drug law at reed smith and served as regulatory counsel for the food and drug administration fda and the center for drug evaluation and research cder he earned his law degree from temple university law school earned his master of public health from george washington university school of public health and received his bachelor’s degree from the college of william and maryegalet corporation patrick sheachief commercial officer mr shea serves as egalet’s chief commercial officer and has held this position since he joined the company in september  mr shea has over two decades of sales marketing market access and commercial operations experience he most recently served as cco at clarus therapeutics inc a men’s health specialty pharmaceutical company prior to clarus he served as vice president of sales and marketing for the us commercial operations of csl behring where he oversaw strategic efforts for sales marketing and managed care business before that he was as senior vice president of sales and marketing for the us pharmaceutical operations at astellas pharmaceuticals and held senior sales and marketing roles at ligand pharmaceuticals and boehringer ingelheim mr shea received his bachelor’s degree in psychology from alfred university careersfind out more about opportunities with egaletcareer contact careersegaletcom quick linkssign up for egalet email alertsinvestor contact iregaletcommedia contact mediaegaletcom egaletus operations  lee road suite  wayne pa  tel general contact infoegaletcom adsxyscroll to top mark strobeck  egalet corporation  zoominfocom mark strobecks phone  address  peoplebyname contact login home people alphabetically s strobeck mark strobeck people directory with over  names record id mark strobeck saddle river rdsaddle river nj  background check  available record id mark strobeck schindler ctsaddle river nj background check  available record id mark strobeck homestead rdwayne pa age  born dec  background check  available record id mark strobeck paradrome stcincinnati oh age  born dec  background check  available record id mark strobeck windsor ctglen mills pa age  born  background check  available record id mark g strobeck columbine drhercules ca age  born background check  available record id mark strobeck schindler ctsaddle river nj background check  available record id mark strobeck saddle river rdsaddle river nj  background check  available record id mark strobeck homestead rdwayne pa age  born dec  background check  available record id mark strobeck paradrome stcincinnati oh age  born dec  background check  available record id mark strobeck windsor ctglen mills pa age  born  background check  available record id mark g strobeck columbine drhercules ca age  born background check  available record id mark strobeck homesteadwayne pa age  born dec  background check  available record id mark strobeck callerymalvern pa age  born dec  background check  available record id mark strobeck windsorglen mills pa age  born  background check  available record id mark strobeck saddle riversaddle river nj age  born dec  background check  available record id mark strobeck washingtonconshohocken pa  background check  available record id mark strobeck paradromecincinnati oh age  born dec  background check  available record id mark strobeck schindlersaddle river nj age  born dec  background check  available record id mark strobeck chathamardmore pa age  born dec  background check  available record id mark g strobeck columbinehercules ca age  born  background check  available record id mark strobeck saddle river rdsaddle river nj  background check  available record id mark strobeck paradrome stcincinnati oh age  born dec  background check  available record id mark strobeck windsor ctglen mills pa age  born  background check  available record id mark strobeck homestead rdwayne pa age  born dec  background check  available record id mark strobeck schindler ctsaddle river nj background check  available record id mark g strobeck columbine drhercules ca age  born background check  available record id mark strobeck schindler ctsaddle river nj background check  available record id mark strobeck saddle river rdsaddle river nj  background check  available record id mark strobeck homestead rdwayne pa age  born dec  background check  available record id mark strobeck paradrome stcincinnati oh age  born dec  background check  available record id mark strobeck windsor ctglen mills pa age  born  background check  available record id mark g strobeck columbine drhercules ca age  born background check  available      total records available tweet testimonials read testimonials from real customers who already used our services read more webmasters earn  commission on every sale you drive to our website weekly payouts read more mobile version visit us from your smart phone anywhere you are read more recent lookups check out the most recent reverse phone lookups on peoplebynamecom read more home mobile version phone directory people directory remove information terms of service privacy policy affiliate program about us member login frequently asked questions contact us testimonials careers product  services volume discounts site map  peoplebyname all rights reserved  topaz pharmaceuticals names dr mark strobeck chief business officer topaz pharmaceuticals names dr mark strobeck chief business officer  executive to focus on corporate and business development  jan    et from topaz pharmaceuticals inc horsham pa jan   prnewswire  topaz pharmaceuticals inc a privately held specialty pharmaceutical company focused on dermatology and pediatrics today announced that mark strobeck phd has been appointed vice president and chief business officer in his new role dr strobeck will report to robert radie president and chief executive officer and will be responsible for managing business development corporate strategy and financings we are pleased to welcome to the topaz management team mark a proven leader with a significant track record of success who will lead our business development efforts said robert radie president and chief executive officer of topaz with our lead product candidate nearing the final stage of development we are building our commercial capabilities and interested in extending our business development reach dr strobeck has decades of experience in the pharmaceutical and financial industry most recently he served as chief business officer of trevena inc a pharmaceutical company dedicated to the discovery and development of gpcr biased ligands before joining trevena he served as vice president of business development at glaxosmithkline gsk where he led the business development efforts for the companys clinical and preclinical stage assets he also served as vice president of business development for the center of excellence for external drug discovery a research and development division within gsk prior to this role dr strobeck was a principal at sr one ltd the wholly owned venture capital arm of gsk dr strobeck earned a phd in pharmacology and cell biophysics from the university of cincinnati he completed a postdoctoral fellowship in cardiovascular medicine at the university of pennsylvania and has a bachelors degree from st lawrence university about topaz pharmaceuticals topaz pharmaceuticals inc is a privately held specialty pharmaceutical company focused on developing and commercializing treatments primarily for pediatric and dermatology markets the companys lead investigational product is a topical cream formulation of ivermectin currently under development for the treatment of head lice in children and adults which affects between six and  million people every year the company has recently concluded two phase  studies of ivermectin for this potential indication and expects to file a new drug application this year topaz headquartered in horsham pa is backed by toptier investors including aisling capital and fidelity biosciences for more information about topaz pharmaceuticals inc please visit wwwtopazpharmacom contact information e blair schoeb tel  blairbiotechcommcom source topaz pharmaceuticals inc related links httpwwwtopazpharmacom view table fullscreen view table fullscreen journalists and bloggers the news you need when you need it join pr newswire for journalists to access all of the free services designated to make your job easier in need of subject matter experts for your story submit a free profnet request and find the sources you need learn more jun    et preview topaz pharmaceuticals announces new drug application for the treatment of head lice accepted by fda dec    et preview topaz pharmaceuticals announces completion of pivotal phase  trials of ivermectin topical cream my news release contains wide tables view fullscreen looking to send a news release with pr newswire take advantage of the worlds leading distribution platform sign up to get started request more information have an account log in search searching for your content advanced search topaz pharmaceuticals names dr mark strobeck chief business officer employer login post jobs job seeker login sign up search life sciences jobs search job title only radius miles km  news  news by subject  news by disease   news by date  search news get our freeindustry enewsletter email       topaz pharmaceuticals names dr mark strobeck chief business officer tweet   am horsham pa jan   prnewswire  topaz pharmaceuticals inc a privately held specialty pharmaceutical company focused on dermatology and pediatrics today announced that mark strobeck phd has been appointed vice president and chief business officer in his new role dr strobeck will report to robert radie president and chief executive officer and will be responsible for managing business development corporate strategy and financings we are pleased to welcome to the topaz management team mark a proven leader with a significant track record of success who will lead our business development efforts said robert radie president and chief executive officer of topaz with our lead product candidate nearing the final stage of development we are building our commercial capabilities and interested in extending our business development reach dr strobeck has decades of experience in the pharmaceutical and financial industry most recently he served as chief business officer of trevena inc a pharmaceutical company dedicated to the discovery and development of gpcr biased ligands before joining trevena he served as vice president of business development at glaxosmithkline gsk where he led the business development efforts for the companys clinical and preclinical stage assets he also served as vice president of business development for the center of excellence for external drug discovery a research and development division within gsk prior to this role dr strobeck was a principal at sr one ltd the wholly owned venture capital arm of gsk dr strobeck earned a phd in pharmacology and cell biophysics from the university of cincinnati he completed a postdoctoral fellowship in cardiovascular medicine at the university of pennsylvania and has a bachelors degree from st lawrence university about topaz pharmaceuticals topaz pharmaceuticals inc is a privately held specialty pharmaceutical company focused on developing and commercializing treatments primarily for pediatric and dermatology markets the companys lead investigational product is a topical cream formulation of ivermectin currently under development for the treatment of head lice in children and adults which affects between six and  million people every year the company has recently concluded two phase  studies of ivermectin for this potential indication and expects to file a new drug application this year topaz headquartered in horsham pa is backed by toptier investors including aisling capital and fidelity biosciences for more information about topaz pharmaceuticals inc please visit wwwtopazpharmacom contact information e blair schoeb tel  blairbiotechcommcomsource topaz pharmaceuticals inc read at biospacecom related news topaz pharmaceuticals names bob radie chief executive officer biogen idec inc massachusetts biib names heads of research corporate development after restructuring topaz pharmaceuticals announces completion of pivotal phase  trials of ivermectin topical cream sohm promotes high performance vp as new ceo of us india and global operations topaz pharmaceuticals announces positive data from topical ivermectin trials presented at society of pediatric dermatology affymax inc affy announces appointment of john orwin as ceo and a member of the board of directors topaz pharmaceuticals receives  million series a financing shangpharma announces appointment of new chief financial officer and promotion of kevin chen as president fda approves phase i clinical trial of topaz pharmaceuticals new head lice treatment karyopharm therapeutics inc appoints michael kauffman md phd as chief executive officer please enable javascript to view the comments powered by disqus comments powered by disqus • biospacecom • topaz pharmaceuticals   • biotechpharma  personnel                 microsoft personalized ad preferences to opt out of personalized ads in this browser your browser history must allow firstparty and thirdparty cookies and you must have your browsing experience set to not delete browsing history on exit instructions for enabling cookies and configuring your browsing history may be available in your browsers settings privacy or help documentation sign in hold on… we’re sorry but this didn’t work you can’t turn off personalized ads right now because your browser is currently blocking thirdparty cookies we can help you fix this issue let’s get started depending on what browser you use open options or settings make sure that thirdparty cookies are not blocked anymore to find out how search your browser’s help revisit httpchoicemicrosoftcomoptout and then on the “personalized ads in this browser” tile click off ext about our ads to create a more customized online experience some of the ads you may receive on microsoft websites and apps are tailored to your previous activities searches and site visits youre in control and heres where you can make the advertising choice thats right for you ext where can i learn more about advertising on microsoft websites and apps microsoft partners with oath appnexus and other third party service providers to help present customized content and display advertisements on msn outlookcom and other websites and apps microsoft also delivers search ads to bing and our search syndication partners learn more about microsoft’s privacy practices here you can learn more about interestbased ads from oath and appnexus in their privacy statements oath and appnexus what choices do i have about interestbased advertising on this page you can opt out of receiving interest based advertising from microsoft you can also opt out of receiving interestbased advertising from all selfregulatory members including microsoft oath appnexus and other third party ad networks at the following sites in the us digital advertising alliance daa in europe european interactive digital advertising alliance edaa in canada ad choices digital advertising alliance of canada daac you can control interestbased advertising in windows apps by turning off the advertising id in windows settings more choices do you want personalized ads from other companies questions if you have a privacy question or a question for the chief privacy officer of microsoft please contact us by using our web form we will respond to questions within  days ext personalized ads in this browser off optout is currently unavailable please try again later control the personalized ads setting for this web browser learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off ext personalized ads wherever i use my microsoft account off sign in to change optout is currently unavailable please try again later control the personalized ads setting that applies when you are signed in on any computer or device with your microsoft account including windows windows phone xbox and other devices learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off if you choose “generic” ads and use a browser your choice applies to everyone when using that browser as long as you do not clear your cookies ext personalized ads in windows in your windows settings you can turn off personalized ads that appear in apps on this device you’ll still see ads but they won’t be personalized anymore if you have windows  access the charms by touching or moving your pointer to the right edge of the screen click or tap settings and then click or tap change pc settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have windows  click or tap the start button click or tap settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have a windows mobile device go to settings tap on privacy tap on advertising id and then turn off let apps use my advertising id for experiences across apps if you want to turn off personalized ads from microsoft wherever you use your microsoft account including apps on windows windows phone xbox and other devices you can do so by selecting the microsoft account option above ext legal privacy  cookies   microsoft egalet appoints mark strobeck phd to executive vice president and chief operating officer egalet appoints mark strobeck phd to executive vice president and chief operating officer oct    et from egalet corporation egalet appoints mark strobeck phd to executive vice president and chief operating officer     facebook twitter pinterest egalet appoints mark strobeck phd to executive vice president and chief operating officer wayne pa oct   prnewswire  egalet corporation nasdaq eglt egalet a fully integrated specialty pharmaceutical company focused on discovering developing and commercializing innovative pain treatments announced the promotion of mark strobeck phd to executive vice president and chief operating officer coo in his new role dr strobeck will be responsible for managing operations and will continue to report to bob radie president and chief executive officer since joining egalet mark has made substantial contributions to the growth of egalet said bob radie president and chief executive officer of egalet with his industry experience and leadership skills mark will play a critical role as coo as we continue to grow and transform the company dr strobeck joined egalet in february of  as chief business officer cbo prior to egalet he served as president chief executive officer and director of corridor pharmaceuticals inc a drug discovery company that was sold to astrazeneca before that he was cbo of topaz pharmaceuticals inc a specialty pharmaceutical company that was sold to sanofi pasteur prior to topaz he held executive leadership and business development positions at trevena inc and glaxosmithkline gsk before working at these healthcare companies dr strobeck was a venture capitalist at sr one ltd the wholly owned venture capital arm of gsk and euclid sr partners he earned a phd in pharmacology and cell biophysics from the university of cincinnati completed a postdoctoral fellowship in cardiovascular medicine at the university of pennsylvania and received his bachelors degree from st lawrence university about egalet egalet a fully integrated specialty pharmaceutical company is focused on developing manufacturing and commercializing innovative pain treatments the company has two approved products oxaydo™ oxycodone hci usp tablets for oral use only –cii and sprix® ketorolac tromethamine nasal spray in addition using egalets proprietary guardian™ technology the company is developing a pipeline of clinicalstage opioidbased product candidates that are specifically designed to deter abuse by physical and chemical manipulation the lead programs arymo® formerly known as egalet an abusedeterrent extendedrelease oral morphine formulation and egalet an abusedeterrent extendedrelease oral oxycodone formulation are in latestage clinical development for the management of pain severe enough to require daily aroundtheclock opioid treatment and for which alternative treatments are inadequate egalets guardian technology can be applied broadly across different classes of pharmaceutical products and can be used to develop combination products that include multiple active pharmaceutical ingredients with similar or different release profiles full additional information on egalet please visit egaletcom for full prescribing information on sprix please visit sprixcom and for oxaydo please visit oxaydocom for full prescribing information on sprix including the black box warning please visit sprixcom for full prescribing information on oxaydo please visit oxaydocom safe harbor statements included in this press release including but not limited to upcoming milestones that are not historical in nature are forwardlooking statements within the meaning of the private securities litigation reform act of  these forwardlooking statements are based on managements current expectations and are subject to known and unknown uncertainties and risks actual results could differ materially from those discussed due to a number of factors including but not limited to the success of egalets clinical trials including the timely recruitment of trial subjects and meeting the timelines therefor egalets ability to obtain regulatory approval of egalets product candidates egalets ability to maintain the intellectual property position of egalets products and product candidates egalets ability to identify and reliance upon qualified third parties to manufacture its products egalets ability to service its debt obligations egalets ability to find and hire qualified sales professionals the receptivity in the marketplace and among physicians to egalets products the success of products which compete with egalets that are or become available general market conditions and other risk factors described in egalets filings with the united states securities and exchange commission egalet assumes no obligation to update or revise any forwardlookingstatements contained in this press release whether as a result of new information or future events except as may be required by law investor and media contact e blair clarkschoeb senior vice president communications email bcsegaletcom tel  photo  httpphotosprnewswirecomprnh  source egalet corporation related links httpwwwegaletcom view table fullscreen view table fullscreen journalists and bloggers the news you need when you need it join pr newswire for journalists to access all of the free services designated to make your job easier in need of subject matter experts for your story submit a free profnet request and find the sources you need learn more oct    et preview egalet to host conference call and webcast to discuss third quarter  financial results on november   sep    et preview egalet provides commercial update on sprix® nasal spray and oxaydo™ along with pipeline review at investor day my news release contains wide tables view fullscreen read more jul    et egalet to host conference call and webcast on august   to jul    et egalet announces closing of  million public equity offering jul    et egalet announces pricing of public offering of common stock and looking to send a news release with pr newswire take advantage of the worlds leading distribution platform sign up to get started request more information have an account log in search searching for your content advanced search mark strobeck mstrobeck  twitter skip to content home home home current page moments moments moments current page search query search twitter saved searches remove in this conversation verified accountprotected tweets  suggested users verified accountprotected tweets  verified accountprotected tweets  language english bahasa indonesia bahasa melayu català čeština dansk deutsch english uk español filipino français hrvatski italiano magyar nederlands norsk polski português română slovenčina suomi svenska tiếng việt türkçe ελληνικά български език русский српски українська мова עִבְרִית العربية فارسی मराठी हिन्दी বাংলা ગુજરાતી தமிழ் ಕನ್ನಡ ภาษาไทย 한국어    have an account log in have an account remember me · forgot password new to twitter sign up mark strobeck mstrobeck tweets tweets current page  following following  followers followers  likes likes    more likes unmute mstrobeck mute mstrobeck follow following unfollow blocked unblock pending cancel mark strobeck mstrobeck joined february   photo or video photos and videos tweets tweets tweets current page tweets  replies media you blocked mstrobeck are you sure you want to view these tweets viewing tweets wont unblock mstrobeck yes view profile close mark strobeck followed mark strobeck retweeted egalet corporation‏ egaletcorp jul  more copy link to tweet embed tweet egalet corporation retweeted peter hsu full study results from tufts center for the study of drug development httpcsddtuftsedu httpstwittercomphsustatus … egalet corporation added peter hsu phsu bgov insurers arent covering safer opioids report says httpswwwbgovcomcorenewsarticlesotchjk … lilbyington opioids insurers opioidcrisis fda  replies  retweets  likes reply retweet  retweeted  like  liked  thanks twitter will use this to make your timeline better undo mark strobeck retweeted egalet corporation‏ egaletcorp jul  more copy link to tweet embed tweet theacpa roundtable references  of chronic pain patients experience issues getting access to their opioid medshttpbitlytbujvf   replies  retweets  likes reply retweet  retweeted  like  liked  thanks twitter will use this to make your timeline better undo mark strobeck retweeted egalet corporation‏ egaletcorp jul  more copy link to tweet embed tweet study lack of willingness by insurers to reimburse ad opioids seen as a primary challenge limiting uptakehttpbitlyttoodv   replies  retweets  likes reply retweet  retweeted  like  liked  thanks twitter will use this to make your timeline better undo mark strobeck retweeted egalet corporation‏ egaletcorp jul  more copy link to tweet embed tweet usfda strong support of transition of conventional opioids to majority with meaningful abusedeterrent properties httpbitlytgobs   replies  retweets  likes reply retweet  retweeted  like  liked  thanks twitter will use this to make your timeline better undo mark strobeck retweeted addiction medicine‏verified account asamorg jul  more copy link to tweet embed tweet new data from the cdcgov shows  million americans engaged in nonmedical use of prescription opioids the last monthpictwittercomegzrkadk  reply  retweets  likes reply  retweet  retweeted  like  liked  thanks twitter will use this to make your timeline better undo mark strobeck retweeted fda law blog‏ fdalawblog jul  more copy link to tweet embed tweet claad petitions fda on transition to abusedeterrent opioids  httpstinyurlcomyvtpj   replies  retweets  likes reply retweet  retweeted  like  liked  thanks twitter will use this to make your timeline better undo mark strobeck retweeted egalet corporation‏ egaletcorp jun  more copy link to tweet embed tweet read the latest news from egalet about our partnership with ascend therapeutics to copromote one of our products httpegaletinvestorroomcomegaletpartnerswithascendtherapeuticsrusllctocopromotesprixrnasalspray …  replies  retweet  likes reply retweet  retweeted  like  liked  thanks twitter will use this to make your timeline better undo mark strobeck retweeted phl business journal‏ phlbizjournal jun  more copy link to tweet embed tweet patents piling up for wayne maker of abusedeterrent medicines httpbizjuspc  via phlbizjgeorgepictwittercomgrgheo  replies  retweets  likes reply retweet  retweeted  like  liked  thanks twitter will use this to make your timeline better undo mark strobeck retweeted egalet corporation‏ egaletcorp jun  more copy link to tweet embed tweet chronic pain patients say opioid crackdown is hurting themhttpwwwchicagotribunecomlifestyleshealthctopioidpatientsbacklashmetstoryhtml …  replies  retweets  like reply retweet  retweeted  like  liked  thanks twitter will use this to make your timeline better undo mark strobeck retweeted david dusek‏ golfweekdusek may  more copy link to tweet embed tweet tbt this greens fee ticket is from a round at stlawrenceu that i played the day before i graduated in  been in my bag ever sincepictwittercomukwevdswu  replies  retweets  likes reply  retweet  retweeted  like  liked  thanks twitter will use this to make your timeline better undo mark strobeck retweeted egalet corporation‏ egaletcorp may  more copy link to tweet embed tweet new data released today at americanpainsoc about harm reduction modeling analysis read our press release here httpbitlypqmvng   replies  retweets  likes reply retweet  retweeted  like  liked  thanks twitter will use this to make your timeline better undo mark strobeck retweeted egalet corporation‏ egaletcorp may  more copy link to tweet embed tweet happening now were presenting americanpainsoc poster session httpbitlypqmvng pictwittercomfqcwvwc  replies  retweets  likes reply retweet  retweeted  like  liked  thanks twitter will use this to make your timeline better undo mark strobeck retweeted egalet corporation‏ egaletcorp may  more copy link to tweet embed tweet data published in two publications now available read more here httpbitlyqsftv   replies  retweets  likes reply retweet  retweeted  like  liked  thanks twitter will use this to make your timeline better undo mark strobeck retweeted meg tirrell‏verified account megtirrell may  more copy link to tweet embed tweet meg tirrell retweeted lydia ramsey every time a new one of these comes out it is more complicated than the lasthttpstwittercomlydiaramseystatus … meg tirrell added lydia ramseyverified account lydiaramsey jamacurrent tackling the complicated world of drug distribution httpjamanetworkcomjournalsjamafullarticle … pictwittercomrjfhlxdem  replies  retweets  likes reply  retweet  retweeted  like  liked  thanks twitter will use this to make your timeline better undo mark strobeck‏ mstrobeck may  more copy link to tweet embed tweet empower patients not icer via forbeshttpwwwforbescomsiteseconostatsempowerpatientsnoticerbeeaff …  replies  retweets  likes reply retweet retweeted like liked thanks twitter will use this to make your timeline better undo mark strobeck‏ mstrobeck may  more copy link to tweet embed tweet icer perpetuates the opioid crisishttpsmorningconsultcomopinionsicerperpetuatesopioidcrisis …  replies  retweets  likes reply retweet retweeted like liked thanks twitter will use this to make your timeline better undo mark strobeck retweeted phrma‏verified account phrma may  more copy link to tweet embed tweet icymi forbes drug prices are growing at the slowest rate in years heres why it doesnt feel that wayhttpbitlyphlccu   replies  retweets  likes reply  retweet  retweeted  like  liked  thanks twitter will use this to make your timeline better undo mark strobeck retweeted egalet corporation‏ egaletcorp apr  more copy link to tweet embed tweet the national prescription drug take back day is this saturday find a collection site near you httpbitlycicpz pictwittercomykcxbsxvno  reply  retweets  likes reply  retweet  retweeted  like  liked  thanks twitter will use this to make your timeline better undo mark strobeck retweeted egalet corporation‏ egaletcorp mar  more copy link to tweet embed tweet we are looking forward to ringing the nasdaq bellpictwittercomqiljexkikm  reply  retweets  likes reply  retweet  retweeted  like  liked  thanks twitter will use this to make your timeline better undo mark strobeck retweeted nasdaq‏verified account nasdaq mar  more copy link to tweet embed tweet embed video egaletcorp ringing the nasdaq closing bell egltpictwittercomnqrbnmlxr  replies  retweets  likes reply  retweet  retweeted  like  liked  thanks twitter will use this to make your timeline better undo mstrobeck hasnt tweeted yet back to top ↑ loading seems to be taking a while twitter may be over capacity or experiencing a momentary hiccup try again or visit twitter status for more information new to twitter sign up now to get your own personalized timeline sign up you may also like · refresh false   twitter about help center terms privacy policy cookies ads info close choose a trend location dismiss close previous next close go to a persons profile saved searches remove in this conversation verified accountprotected tweets  suggested users verified accountprotected tweets  verified accountprotected tweets  close promote this tweet close block cancel block add a location to your tweets when you tweet with a location twitter stores that location you can switch location onoff before each tweet and always have the option to delete your location history learn more turn location on not now close share location results from send close your lists close create a new list list name description under  characters optional privacy public · anyone can follow this list private · only you can access this list save list close close copy link to tweet heres the url for this tweet copy it to easily share with friends close embed this tweet embed this video add this tweet to your website by copying the code below learn more add this video to your website by copying the code below learn more hmm there was a problem reaching the server try again include parent tweet include media by embedding twitter content in your website or app you are agreeing to the twitter developer agreement and developer policy preview close why youre seeing this ad close log in to twitter remember me · forgot password dont have an account sign up » close sign up for twitter not on twitter sign up tune into the things you care about and get updates as they happen sign up have an account log in » close twoway sending and receiving short codes country code for customers of united states  any canada  any united kingdom  vodafone orange  o brazil  nextel tim haiti  digicel voila ireland  vodafone o india  bharti airtel videocon reliance indonesia  axis  telkomsel indosat xl axiata italy  wind  vodafone » see sms short codes for other countries close confirmation close   close skip all welcome home this timeline is where you’ll spend most of your time getting instant updates about what matters to you tweets not working for you hover over the profile pic and click the following button to unfollow any account say a lot with a little when you see a tweet you love tap the heart — it lets the person who wrote it know you shared the love spread the word the fastest way to share someone else’s tweet with your followers is with a retweet tap the icon to send it instantly join the conversation add your thoughts about any tweet with a reply find a topic you’re passionate about and jump right in learn the latest get instant insight into what people are talking about now get more of what you love follow more accounts to get instant updates about topics you care about find whats happening see the latest conversations about any topic instantly never miss a moment catch up instantly on the best stories happening as they unfold back next next tweet from user mark strobeck of egalet corp executive profile   welcome company news company site premium log in membership home portfolio stocks bonds funds etfs cef markets tools real life finance discuss investing ideas fund analyst picks picks by category fund pick performance picks  pans enewsletter fund spy column fund spy book bond squad fund video reports fundinvestor newsletter etf investing fund family experts fund reports all fund analyst reports fund stewardship reports fund ratings highestrated value highestrated growth highestrated largecap highestrated midcap highestrated smallcap foreign fund standouts star rating performance rating methodology fund performance top month performers top ytd performers top year performers top year performers top year performers fund category returns biggest daily nav changes closedend funds exchangetraded funds quarterly market outlook fund screeners basic screeners fund screener longterm winners solid smallgrowth funds conservative bond funds premium screeners premium fund screener index funds hidden gems lowerrisk foreign funds video center egalet corp  eglt add to portfolioget email alertsprint this pagepdf reportdata questionquotechartstock analysisperformancekey ratiosfinancialsvaluationinsidersownershipfilingsbondsoverviewexecutive compensationinsider activitykey executivesboard of directorscommittees key executives  mark strobeck mark strobeck executive vice president and chief operating officer profile connections biography mark strobeck phd dr strobeck is our executive vice president and chief operating officer a position he has held since september  and previously served as our chief business officer from january  to september  prior to his employment at egalet he served as our advisor from june  to december  from january  to december  dr strobeck served as president and chief executive officer and a director of corridor pharmaceuticals inc which was acquired by astrazeneca in  from december  to october  dr strobeck served as chief business officer of topaz pharmaceuticals inc a specialty pharmaceutical company acquired by sanofi pasteur in the fourth quarter of  from june  to november  and october  to january  dr strobeck worked as a consultant from january  to may  dr strobeck served as chief business officer of trevena inc a pharmaceutical company prior to joining trevena dr strobeck held management roles at glaxosmithkline sr one limited and euclidsr partners lp dr strobeck currently serves on the board of directors of horse power for life a nonprofit organization dedicated to improving the quality of life for individuals diagnosed with cancer a position he has held since  dr strobeck received his bs in biology from st lawrence university and his phd in pharmacology from the university of cincinnati and completed his postdoctoral fellowship at the university of pennsylvania board membership mark strobeck is not a member of any boards   we value your feedback let us know what you think site directory site map our products corrections help advertising opportunities licensing opportunities glossary rss mobile portfolio affiliate careers international sites australia canada china france germany hong kong italy the netherlands norway spain uk switzerland stocks by name  ticker  star rating  market cap  stock type  sector  industry mutual funds by star rating  investment style  total assets  category  top holdings  top sectors  symbol  ticker  name etfs by star rating  category  total assets  symbol  ticker  name articles by title  date  author  collection  interest  popularity investment categories by topic  sector  key indicators  user interest  market cap  industry premium stocks by name  ticker  star rating  market cap  stock type  sector  industry premium mutual funds by star rating  investment style  total assets  category  top holdings  top sectors  symbol  ticker  name premium etfs by star rating  category  total assets  symbol  ticker  name popular articles by title  date  author  collection  interest  popularity popular investment categories by topic  sector  key indicators  user interest  market cap  industry independent insightful trusted morningstar provides stock market analysis equity mutual fund and etf research ratings and picks portfolio tools and option hedge fund ira k and  plan research our reliable data and analysis can help both experienced enthusiasts and newcomers  copyright morningstar inc all rights reserved please read our terms of useand privacy policydow jones industrial average sp  nasdaq and morningstar index market barometer quotes are realtime russell  quote is  minutes delayed